Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cord blood platelet gel (CBPG) is a blood-derived biologic product for topical application, produced from allogeneic umbilical cord blood units. It is prepared by concentrating platelets from cord blood, which are then cryopreserved and activated (typically with calcium gluconate) to form a bioactive gel. CBPG contains a high concentration of growth factors, including vascular endothelial growth factor (VEGF) and transforming growth factor (TGF), which promote tissue repair and angiogenesis. Compared to adult-derived platelet-rich plasma (PRP), CBPG is reported to have a distinct growth factor profile and a lower risk of microbiological contamination. It is primarily investigated for the treatment of chronic wounds, such as diabetic foot ulcers, and severe oral mucositis following high-dose chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cord blood platelet gel.